Biomedical subjects

G Flygt

Publications and source records attributed to G Flygt.

3 recordsLinked to original sources

PubMed1990

Felodipine is more effective than hydrochlorothiazide when added to a beta-blocker in treating elderly hypertensive patients.

This randomized, double-blind, parallel-group study compared felodipine and hydrochlorothiazide (HCT) given in addition to a beta-blocker in 134 elderly hypertensive patients aged 56-79 years (mean of 66 +/- 5 years). In the felodipine-treated group (n = 57), supine blood pressure (BP) was reduced from 171 +/- 16/101 +/- 6 mm Hg at randomization to 147 +/- 12/86 +/- 6 mm Hg after 8 weeks, whereas in the HCT-treated group (n = 66), BP was reduced from 170 +/- 4/101 +/- 5 to 151 +/- 16/89 +/- 9 mm Hg. The reduction in diastolic blood pressure (DBP) was significantly greater in the felodipine than in the HCT group (p less than 0.003). In the felodipine-treated group, 87% of the patients were controlled (DBP less than or equal to 90 mm Hg) compared with 58% in the HCT group (p less than 0.001). Reported adverse events were generally mild. Six patients withdrew from the study due to adverse events, five in the felodipine group and one in the HCT group.

Adrenergic beta-Antagonists↗

PubMed1990

Long-term treatment of hypertension with felodipine.

Hypertensive patients who had previously taken part in double-blind, controlled studies were treated with open-label felodipine for 1 year: 377 had felodipine added to a beta-blocker and 94 were receiving monotherapy. In the first group, supine blood pressure (BP), measured at the beginning of the double-blind period, was reduced from 172 +/- 23/107 +/- 8 to 140 +/- 20/86 +/- 8 mm Hg at the end of 1 year of therapy. In the monotherapy group, BP was reduced from 170 +/- 22/101 +/- 7 mm Hg measured before treatment to 149 +/- 17/90 +/- 9 mm Hg after 1 year. The most common adverse experiences that led to withdrawal were peripheral edema, headache, flushing, and dizziness. No development of tolerance was noted.

Blood Pressure↗

PubMed1987

Felodipine versus Moduretic. A double-blind parallel-group multicentre study.

In a double-blind parallel-group study 133 patients with mild to moderate essential hypertension were randomised to felodipine 5mg twice daily or Moduretic mite every morning after a run-in placebo period of 1 to 2 weeks. All previous antihypertensive therapy was withdrawn at the start of the run-in period. After 4 weeks the dose of felodipine was increased to 10mg twice daily, and Moduretic mite was replaced by Moduretic in patients with a diastolic blood pressure of greater than 80mm Hg. On the low dose, the supine blood pressure on felodipine was reduced by 24/14mm Hg from 174/105mm Hg, and on Moduretic mite by 19/11mm Hg from 171/103mm Hg. After the increase in dosage blood pressure was lowered further. There was no statistically significant difference in blood pressure reduction between the 2 groups. Severe adverse drug experiences (ADEs) were few and equally distributed. However, more felodipine patients were withdrawn because of ADEs. Potassium levels decreased and uric acid levels increased significantly in the Moduretic group.

Adult↗